The cost of using satlizumab (Anshiping) for one year

Satralizumab (Satralizumab) A drug used to treat patients 12 years and older with neuromyelitis optica spectrum disorder (NMOSD), an inflammatory disease that primarily affects the optic nerve (the nerve that connects the eye to the brain) and spinal cord. This results in impaired vision, loss of sensation, bladder control, weakness in the limbs, and paralysis. Treatment should therefore be started under the supervision of a doctor experienced in treating NMOSD, and this drug is only available with a prescription.

Satlizumab is available as a solution in a prefilled syringe for injection under the skin in the abdomen (abdomen) or thigh. Treatment begins with three injections every two weeks and then every four weeks at a dose of 120 mg. Patients or their caregivers can inject themselves after receiving training from a medical professional. Vaccinations should be up to date and any infections should be well controlled before starting treatment with satelizumab. Patients should also be monitored for infections during treatment with satelizumab.

The patent drug Saterizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is 120mg (1ml). The price of each box may be more than 10,000 yuan. According to its prescription information, the cost for patients to use it for one year is about one million yuan. The high price will increase the financial burden of patients. The price of each box of Satclizumab's original drug sold overseas is more than 10,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.